Piper Jaffray Companies restated their buy rating on shares of DexCom, Inc. (NASDAQ:DXCM) in a research note issued to investors on Wednesday morning. The brokerage currently has a $78.00 target price on the medical device company’s stock.
Several other research analysts have also commented on DXCM. B. Riley reissued a buy rating and issued a $95.00 price target on shares of DexCom in a research report on Sunday, May 7th. BidaskClub lowered DexCom from a buy rating to a hold rating in a research report on Wednesday, July 5th. Canaccord Genuity reissued a buy rating and issued a $90.00 price target on shares of DexCom in a research report on Wednesday, June 7th. Oppenheimer Holdings, Inc. reissued a buy rating on shares of DexCom in a research report on Thursday, April 13th. Finally, Royal Bank Of Canada reissued an outperform rating and issued a $87.00 price target on shares of DexCom in a research report on Tuesday, April 4th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $89.47.
DexCom (DXCM) traded down 1.44% during midday trading on Wednesday, hitting $70.69. The stock had a trading volume of 1,992,186 shares. DexCom has a 52-week low of $57.68 and a 52-week high of $96.38. The stock’s market cap is $6.11 billion. The company’s 50 day moving average price is $71.68 and its 200-day moving average price is $74.65.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. The firm had revenue of $142.30 million during the quarter, compared to analyst estimates of $143.94 million. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. Analysts forecast that DexCom will post ($0.71) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (NASDAQ:DXCM) Earns “Buy” Rating from Piper Jaffray Companies” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/07/17/dexcom-inc-nasdaqdxcm-earns-buy-rating-from-piper-jaffray-companies.html.
In other DexCom news, insider Terrance H. Gregg sold 15,000 shares of the business’s stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $74.10, for a total transaction of $1,111,500.00. Following the sale, the insider now owns 454,559 shares in the company, valued at approximately $33,682,821.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 8,649 shares of the business’s stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total value of $591,505.11. Following the sale, the chief executive officer now owns 347,329 shares in the company, valued at approximately $23,753,830.31. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,063 shares of company stock worth $3,800,519. Company insiders own 1.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in DexCom during the first quarter valued at $136,000. IFP Advisors Inc boosted its position in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the period. Edmond DE Rothschild Holding S.A. bought a new position in shares of DexCom during the first quarter valued at about $164,000. Mn Services Vermogensbeheer B.V. boosted its position in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the period. Finally, Independent Portfolio Consultants Inc. boosted its position in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the period.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.